tradingkey.logo
tradingkey.logo
Search

GlucoTrack Inc

GCTK
Add to Watchlist
0.650USD
-0.020-2.97%
Close 05/15, 16:00ETQuotes delayed by 15 min
591.95KMarket Cap
LossP/E TTM

GlucoTrack Inc

0.650
-0.020-2.97%
View Detailed Chart
Intraday
1m
30m
1h
D
W
M
D

Today

-2.97%

5 Days

-18.79%

1 Month

-12.40%

6 Months

-87.45%

Year to Date

-83.20%

1 Year

-92.78%

TradingKey Stock Score of GlucoTrack Inc

Currency: USD Updated: 2026-05-15

Key Insights

GlucoTrack Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 213 out of 382 in the Biotechnology & Medical Research industry.Institutional ownership is very high.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

GlucoTrack Inc's Score

Industry at a Glance

Industry Ranking
213 / 382
Overall Ranking
450 / 4482
Industry
Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Neutral

GlucoTrack Inc Highlights

StrengthsRisks
Glucotrack, Inc. is focused on the design, development, and commercialization of technologies for people with diabetes. The Company is engaged in developing a long-term Implantable Continuous Blood Glucose Monitor (CBGM) for people living with Type 1 diabetes and insulin-dependent Type 2 diabetes. Its CBGM is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. Its CBGM technology allows for a less burdensome approach to glucose monitoring. It has also completed four animal studies with evolving prototype systems, all four of which consistently demonstrated a simple implant procedure, functionality, and safety. The Company has also demonstrated continuous glucose sensing in the epidural space via two additional animal trials, both of which demonstrated a simple implant procedure, functionality, and safety.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 0.00.
Fairly Valued
The company’s latest PE is -0.02, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 221.24K shares, increasing 31.18% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 0.00 shares of this stock.

Analyst Rating

Based on 0 analysts
--
Current Rating
--
Target Price
--
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

GlucoTrack Inc News

More news coming soon, stay tuned...

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

GlucoTrack Inc Info

Glucotrack, Inc. is focused on the design, development, and commercialization of technologies for people with diabetes. The Company is engaged in developing a long-term Implantable Continuous Blood Glucose Monitor (CBGM) for people living with Type 1 diabetes and insulin-dependent Type 2 diabetes. Its CBGM is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. Its CBGM technology allows for a less burdensome approach to glucose monitoring. It has also completed four animal studies with evolving prototype systems, all four of which consistently demonstrated a simple implant procedure, functionality, and safety. The Company has also demonstrated continuous glucose sensing in the epidural space via two additional animal trials, both of which demonstrated a simple implant procedure, functionality, and safety.
Ticker SymbolGCTK
CompanyGlucoTrack Inc
CEOGoode (Paul V)
Websitehttps://glucotrack.com/
KeyAI